imiquimod has been researched along with delphinidin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adhami, VM; Chamcheu, JC; Chaves-Rodriquez, MI; Dodwad, SM; Esnault, S; Longley, BJ; Mukhtar, H; Satyshur, KA; Sechi, M; Siddiqui, IA; Syed, DN; Wood, GS | 1 |
1 other study(ies) available for imiquimod and delphinidin
| Article | Year |
|---|---|
Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Anthocyanins; Antioxidants; Binding Sites; Biopsy; Chemotaxis, Leukocyte; Cytokines; Disease Models, Animal; Imiquimod; Immunomodulation; Inflammation Mediators; Mice; Models, Molecular; Molecular Conformation; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psoriasis; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Skin; TOR Serine-Threonine Kinases | 2017 |